Form 4: Spero Therapeutics Director Cynthia Smith Granted 20,000 Restricted Stock Units

Spero Therapeutics Director Cynthia Smith was granted 20,000 restricted stock units (RSUs) on June 12, 2025, increasing her beneficial ownership to 75,000 shares.

Summary

• Cynthia Smith, a Director of Spero Therapeutics, Inc. (SPRO), acquired 20,000 shares of common stock.
• The acquisition occurred on June 12, 2025, and was reported as a transaction made pursuant to a Rule 10b5-1(c) plan.
• These shares are in the form of Restricted Stock Units (RSUs), which represent the right to receive one share of common stock upon vesting.
• The RSUs vest on June 12, 2026, subject to Ms. Smith's continued service through the applicable vesting date.
• The transaction price for the RSUs was $0, which is typical for equity grants.
• Following this transaction, Ms. Smith beneficially owns a total of 75,000 shares of Spero Therapeutics common stock.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive sign of continued commitment and aligns the director's interests with long-term shareholder value, reflecting standard corporate governance practices. It is not a major financial event but indicates stability in board compensation.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Cynthia Smith aligns her interests with those of long-term shareholders, as the value of her compensation is tied to the company's stock performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent equity compensation strategy.

Future Outlook

The document indicates that the 20,000 Restricted Stock Units granted to Cynthia Smith are scheduled to vest on June 12, 2026, contingent upon her continued service to the company.

Industry Context

The grant of Restricted Stock Units (RSUs) to a director is a common and standard practice within the biotechnology and broader corporate sectors for executive and board member compensation. This method is widely used to incentivize long-term commitment and align the interests of directors with the company's performance and shareholder value creation.

Comparison to Industry Standards

• The granting of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a standard practice across the biotechnology and pharmaceutical industries, similar to compensation structures seen at companies like Moderna, BioNTech, or Gilead Sciences for their board members.
• The vesting schedule, contingent on continued service, is also a typical feature of such grants, ensuring retention and ongoing commitment from board members.

Corporate Governance

Related Party Transactions

• The acquisition of 20,000 Restricted Stock Units by Cynthia Smith, a Director of Spero Therapeutics, Inc., constitutes a related party transaction as it involves an equity grant to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 20,000 Restricted Stock Units are expected to vest on June 12, 2026, provided Cynthia Smith continues her service as a director.

Key Dates

Keywords

Spero Therapeutics, SPRO, Cynthia Smith, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Beneficial Ownership